Clinical Trials on HER 2 Positive Advanced Gastric Cancer in Australia
Total 69 results
-
D3 Bio (Wuxi) Co., LtdRecruitingHER-2 Positive Advanced Solid TumorsAustralia, United States, China
-
BeiGeneRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | Advanced Solid Tumor | Non-small Cell Lung Cancer | Hormone Receptor Positive Malignant Neoplasm of Breast | Hormone Receptor Positive Breast Carcinoma | HER2-negative Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive...Australia, United States
-
Novartis PharmaceuticalsCompletedMetastatic Breast Cancer | HER-2 Positive Breast CancerBelgium, Netherlands, Australia, Italy, United States
-
Olema Pharmaceuticals, Inc.NovartisRecruitingAdvanced Breast Cancer | Metastatic Breast Cancer | HR-positive Breast Cancer | HER2-negative Breast CancerUnited States, Australia
-
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyRecruitingHER2-positive Advanced Gastric Cancer | HER2-positive Gastroesophageal Junction AdenocarcinomaAustria, Belgium, Germany, Italy
-
GeneQuantum Healthcare (Suzhou) Co., Ltd.RecruitingHER2-positive Breast Cancer | HER2-positive Biliary Tract Cancer | HER2-Positive Salivary Gland Carcinomas | HER2-Positive Advanced Solid TumorChina, Australia, United States
-
Olema Pharmaceuticals, Inc.RecruitingBreast Cancer | Advanced Breast Cancer | Metastatic Breast Cancer | HER2 Negative Breast Carcinoma | ER Positive Breast CancerUnited States, Korea, Republic of, Australia, Taiwan, Hong Kong, Malaysia, Thailand, Argentina, Belgium, Portugal, Italy
-
Alliance Foundation Trials, LLC.Pfizer; Syneos Health; UNICANCER; German Breast Group; SOLTI Breast Cancer Research... and other collaboratorsActive, not recruitingHER-2 Positive Breast Cancer | Estrogen Receptor Positive Breast CancerUnited States, Spain, France, Italy, Germany, Australia, Portugal, New Zealand
-
Eli Lilly and CompanyCompletedHER-2 Positive Breast Cancer | Hormone Receptor Positive Breast CancerSpain, United States, Korea, Republic of, Belgium, France, Germany, Italy, Australia, Argentina, Canada, United Kingdom, Mexico, Brazil, Greece
-
Novartis PharmaceuticalsCompletedAdvanced Gastric Cancer | Gastro-esophageal Junction CancerUnited States, France, Italy, Taiwan, United Kingdom, Turkey, Germany, Singapore, Australia, Russian Federation, Korea, Republic of, Switzerland, Netherlands, Canada
-
Hoffmann-La RocheRecruitingInoperable, Locally Advanced or Metastatic, ER-positive Breast CancerUnited States, Korea, Republic of, Spain, Australia, Israel
-
Amunix, a Sanofi CompanyMerck Sharp & Dohme LLCRecruitingLocally Advanced or Metastatic HER2-Expressing CancersAustralia, Spain, France, Portugal
-
Molecular Templates, Inc.TerminatedHER2-positive Solid CancersUnited States, Australia, New Zealand
-
Novartis PharmaceuticalsBreast International Group; German Breast Group; SOLTI Breast Cancer Research...CompletedHER2-positive Newly Diagnosed, Primary Breast CancerAustria, Spain, Australia, Germany
-
Institut für Klinische Krebsforschung IKF GmbH...RecruitingAdvanced Gastric or EGJ CancerGermany, Austria, Italy
-
Hoffmann-La RocheRecruitingEstrogen Receptor-Positive, HER2-Negative Advanced Breast CancerBelgium, Korea, Republic of, United States, Canada, China, Italy, France, Brazil, Australia, Argentina, Hong Kong, Portugal, Spain, Taiwan, Costa Rica, Israel, Thailand, Germany, New Zealand, Poland, Chile, Colombia, Guatemala, Hungary, Indi...
-
Hoffmann-La RocheTerminatedEstrogen Receptor-positive (ER+)/Human Epidermal Growth Factor Receptor (HER2)-Negative Locally Advanced or Metastatic Breast CancerCanada, United States, United Kingdom, Australia, Germany
-
AstraZenecaRecruitingER-Positive HER2-Negative Breast CancerUnited States, Israel, Spain, Korea, Republic of, Italy, Poland, Belgium, Norway, Bulgaria, France, Germany, United Kingdom, Japan, Taiwan, Canada, Hungary, Australia, Austria, Portugal, Turkey, Russian Federation, Slovakia, Switzer...
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUnited States, Italy, Korea, Republic of, Canada, Germany, United Kingdom, Australia, Belgium, Brazil, China, Denmark, France, Hong Kong, Portugal, Spain, Taiwan, Turkey, Japan, Argentina, Mexico, Israel, Poland, Russian Federation, A... and more
-
Hoffmann-La RocheActive, not recruitingEstrogen Receptor-Positive, HER2-Negative, Locally Advanced or Metastatic Breast CancerUnited States, Korea, Republic of, China, Poland, Taiwan, Turkey, United Kingdom, Australia, Argentina, Germany, Singapore, Thailand, Israel, Russian Federation, Ukraine, Brazil, South Africa
-
Breast Cancer Trials, Australia and New ZealandRecruitingBreast Cancer | HER2-positive Breast CancerAustralia
-
AstraZenecaRecruitingER+ HER2- Advanced Breast Cancer | High-grade Serous Ovarian Cancer (HGSOC)United Kingdom, Korea, Republic of, Australia, United States, Spain
-
MacroGenicsCompletedHER-2 Positive Breast Cancer | Metastatic NeoplasmUnited States, Spain, Italy, Canada, Israel, Belgium, Germany, Czechia, Austria, Korea, Republic of, Denmark, United Kingdom, Portugal, France, Poland, Netherlands, Finland, Puerto Rico
-
BeiGeneRecruitingBreast Cancer | Small Cell Lung Cancer | Gastric Cancer | Ovarian Cancer | Prostate Cancer | Advanced Solid Tumor | Endometrial Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer | Hormone-receptor-positive Breast CancerUnited States, Australia
-
iOMEDICO AGSeagen Inc.RecruitingHER2-positive Breast CancerGermany, Austria
-
Novartis PharmaceuticalsCompletedMetastatic Colorectal Cancer | Gastric Cancer | Advanced Solid Tumors | Metastatic Breast Cancer | Gastroesophageal Junction Cancer | Recurrent Glioblastoma Multiforme | Advanced Pancreatic Adenocarcinoma | Safety | Triple Negative Metastatic Breast Cancer | Dose Escalation | Preliminary Efficacy | Hormone Receptor...Canada, United Kingdom, Spain, Germany, Italy, Belgium, Australia, United States
-
Bristol-Myers SquibbClovis Oncology, Inc.CompletedAdvanced Gastric CancerUnited States, Israel, Netherlands, Canada, Italy, Australia, Germany, Singapore, Switzerland
-
PfizerTerminatedAdvanced Breast Cancer (Parts 1 and 2) | Advanced Pancreatic Cancer (Part 1) | Advanced Colorectal Cancer (Part 1) | Advanced Cholangiocarcinoma (Part 1) | Advanced Glioblastoma Multiforme (Part 1)United States, Spain, Hong Kong, Belgium, Australia, France
-
AstraZenecaActive, not recruitingER-Positive HER2-Negative Breast CancerAustria, Belgium, France, Germany, Italy, United Kingdom, United States, Canada, India, Taiwan, Russian Federation, Korea, Republic of, Hungary, Japan, Mexico, Turkey, China, Malaysia, Spain, Czechia, Portugal, Poland, Norway, Bulgaria, Slovaki... and more
-
Jules Bordet InstituteHoffmann-La Roche; Breast International Group; Institut Curie; International Drug...SuspendedHER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast CancerKorea, Republic of, France, Israel, Belgium, Switzerland, Australia
-
Incyclix BioRecruitingBreast Cancer | Ovarian Cancer | Solid Tumor | Metastatic Cancer | Advanced Cancer | Breast Cancer Metastatic | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | CCNE1 AmplificationUnited States, Australia
-
PfizerRecruitingLocally Advanced or Metastatic ER+ HER2- Breast Cancer | Locally Advanced or Metastatic Castration-resistant Prostate Cancer | Locally Advanced or Metastatic Non-small Cell Lung CancerUnited States, China, Australia, Korea, Republic of, Japan
-
Novartis PharmaceuticalsCompletedAdvanced Gastric CancerChina, United States, Belgium, France, Taiwan, United Kingdom, Canada, Spain, Italy, Australia, Russian Federation, Thailand, Korea, Republic of, Israel, Germany, Peru, Argentina, Japan, Hong Kong, New Zealand, Mexico, Netherlands
-
Astellas Pharma Global Development, Inc.Active, not recruitingLocally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Locally Advanced Unresectable Gastric Adenocarcinoma or Cancer | Metastatic Gastric Adenocarcinoma or Cancer | Metastatic Gastroesophageal Junction (GEJ) AdenocarcinomaUnited States, Australia, Belgium, Brazil, Canada, Chile, China, Colombia, France, Germany, Israel, Italy, Japan, Korea, Republic of, Mexico, Peru, Poland, Spain, Taiwan, United Kingdom
-
Olema Pharmaceuticals, Inc.Active, not recruitingHormone Receptor Positive Breast Carcinoma | HER2-negative Breast CancerUnited States, Australia
-
BeiGeneCompletedAdvanced or Inoperable Gastric CancerUnited States, Hungary, Spain, China, Hong Kong, Japan, Australia, Taiwan, Belgium, Czechia, Singapore, France, Poland, United Kingdom, Romania, Russian Federation, Georgia
-
Enliven TherapeuticsRecruitingHER2-positive Metastatic Breast Cancer | HER2 Gene Mutation | HER2 Mutant Non-small Cell Lung Cancer | HER2 AmplificationUnited States, Spain, Korea, Republic of, Taiwan, Italy, Australia, France
-
AstraZenecaDaiichi Sankyo Co., Ltd.Active, not recruitingPart 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric, Colorectal Cancer | Part 2: HER2 Expressing/Amplified Solid Tumors Excluding Breast, Gastric, Colorectal CancerBelgium, United States, Poland, India, Taiwan, Thailand, Korea, Republic of, Czechia, Russian Federation, United Kingdom, Spain, Australia, Canada, Italy, Netherlands
-
Ambrx, Inc.RecruitingHER2 Positive Metastatic Breast CancerUnited States, Korea, Republic of, France, Australia
-
German Breast GroupPfizer; AGO Study Group; Breast International Group; NSABP Foundation IncCompletedBreast Cancer | Hormonreceptor Positive | Her2-normal | Postneoadjuvant Treatment With CDK 4/6 Inhibitor | CPS-EG ScoreUnited States, Australia, Austria, Canada, France, Germany, Ireland, Japan, Korea, Republic of, Spain, United Kingdom
-
Genentech, Inc.RecruitingMelanoma | Cervical Cancer | HCC | Gastric Cancer | Esophageal Cancer | NSCLC | Urothelial Carcinoma | HNSCC | Locally Advanced or Metastatic Solid Tumors | TNBC | Clear Cell RCCKorea, Republic of, Netherlands, Spain, United States, Australia, Canada, Belgium
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedUnresectable, Recurrent, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | Gastric Cancer Third LineSpain, Italy, Australia, Korea, Republic of, Belgium, France, Poland, United States, Czechia, Germany
-
Merrimack PharmaceuticalsTerminatedBreast Cancer | HER2 Positive Breast CancerSpain, United States, Italy, France, Canada, Belgium, Austria, Germany, Czech Republic
-
DualityBio Inc.RecruitingHER2-positive Advanced Solid TumorChina, United States, Australia, Puerto Rico
-
Seagen Inc.Merck Sharp & Dohme LLCRecruitingHER2 Positive Breast CancerUnited States, Taiwan, Canada, Korea, Republic of, Austria, China, Spain, Japan, France, Italy, Switzerland, Australia, Belgium, Brazil, Germany, Portugal, United Kingdom, Netherlands, Czechia, Greece, Chile, Finland, Poland
-
Keythera Pharmaceuticals (Australia) Pty LtdRecruitingGastric Cancer | Colorectal Cancer | Lung Cancer | Bladder Cancer | Advanced Solid Tumor | Squamous Cell Carcinoma of the EsophagusAustralia
-
Novartis PharmaceuticalsCompletedAdvanced Solid Tumors With Alterations of FGFR1, 2 and or 3 | Squamous Lung Cancer With FGFR1 Amplification | Bladder Cancer With FGFR3 Mutation or Fusion | Advanced Solid Tumors With FGFR1 Amplication | Advanced Solid Tumors With FGFR2 Amplication | Advanced Solid Tumors With FGFR3 MutationFrance, Spain, Taiwan, Germany, Netherlands, Singapore, United States, Australia, Korea, Republic of, Thailand, Israel, Italy, Turkey, Austria
-
Seagen Inc.RecruitingHER2-positive Breast CancerUnited States, Australia, Austria, Belgium, Canada, China, Denmark, France, Germany, Israel, Italy, Japan, Korea, Republic of, Netherlands, Singapore, Spain, Sweden, Switzerland, Taiwan, United Kingdom
-
AstraZenecaCompletedEGFR Mutation Positive Advanced Non Small Cell Lung CancerUnited States, Korea, Republic of, Taiwan, Australia
-
Seagen Inc.CompletedHER2 Positive Breast CancerUnited States, Spain, Belgium, Germany, Israel, France, United Kingdom, Austria, Denmark, Italy, Australia, Canada, Czechia, Portugal, Switzerland